WO2003090665A3 - Regulation der erythrozyten-apoptose - Google Patents

Regulation der erythrozyten-apoptose Download PDF

Info

Publication number
WO2003090665A3
WO2003090665A3 PCT/EP2003/004390 EP0304390W WO03090665A3 WO 2003090665 A3 WO2003090665 A3 WO 2003090665A3 EP 0304390 W EP0304390 W EP 0304390W WO 03090665 A3 WO03090665 A3 WO 03090665A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
apoptosis
erythrocyte
erythrocyte apoptosis
cation channels
Prior art date
Application number
PCT/EP2003/004390
Other languages
English (en)
French (fr)
Other versions
WO2003090665A2 (de
Inventor
Florian Lang
Karl Lang
Philip Lang
Stephan Huber
Original Assignee
Florian Lang
Karl Lang
Philip Lang
Stephan Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang, Karl Lang, Philip Lang, Stephan Huber filed Critical Florian Lang
Priority to AU2003232212A priority Critical patent/AU2003232212A1/en
Priority to EP03747127A priority patent/EP1530473A2/de
Publication of WO2003090665A2 publication Critical patent/WO2003090665A2/de
Publication of WO2003090665A3 publication Critical patent/WO2003090665A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung einer Substanz zum Nachweis von Kationenkanälen sowie die Verwendung eines Wirkstoffes zur Beeinflussung von Kationenkanälen zur Vorbeugung oder Behandlung von Erkrankungen, die mit einer gestörten Regulation der Apoptose in Zusammenhang stehen.
PCT/EP2003/004390 2002-04-26 2003-04-28 Regulation der erythrozyten-apoptose WO2003090665A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003232212A AU2003232212A1 (en) 2002-04-26 2003-04-28 Regulation of erythrocyte apoptosis
EP03747127A EP1530473A2 (de) 2002-04-26 2003-04-28 Regulation der erythrozyten-apoptose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10219545A DE10219545A1 (de) 2002-04-26 2002-04-26 Regulation der Apoptose
DE10219545.5 2002-04-26

Publications (2)

Publication Number Publication Date
WO2003090665A2 WO2003090665A2 (de) 2003-11-06
WO2003090665A3 true WO2003090665A3 (de) 2004-01-08

Family

ID=28798961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004390 WO2003090665A2 (de) 2002-04-26 2003-04-28 Regulation der erythrozyten-apoptose

Country Status (4)

Country Link
EP (1) EP1530473A2 (de)
AU (1) AU2003232212A1 (de)
DE (1) DE10219545A1 (de)
WO (1) WO2003090665A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079463A1 (en) 2015-11-04 2017-05-11 Prescient Pharma Llc Anti-aging compositions and methods for using same

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB611518A (en) * 1945-11-20 1948-11-01 Lilly Co Eli Manufacture of quinacrine
EP0310410A2 (de) * 1987-10-02 1989-04-05 Kawate, Tsuneyoshi Kalziumbeschleunigte Kalium-Flut-Kontrolle von geschädigten Körperzellen
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
WO1992021362A1 (en) * 1991-06-03 1992-12-10 Farmitalia Carlo Erba S.R.L. Nerve growth factor for use in the prevention and treatment of viral infections
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
EP0688766A1 (de) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1997017087A1 (en) * 1995-11-07 1997-05-15 Genentech, Inc. Stabilizing formulation for ngf
EP0799836A1 (de) * 1994-12-29 1997-10-08 Yamanouchi Pharmaceutical Co. Ltd. Neuer monoklonaler antikörper welcher einen inhibitorischen effekt auf die typ ii phospholipase a2 zeigt und ein ptotein welches einen teil von diesem beinhaltet
WO1999011291A1 (en) * 1997-09-04 1999-03-11 The Trustees Of The University Of Pennsylvania A method of inducing apoptosis in human brain tumor cells using nerve growth factor
EP0937456A1 (de) * 1998-02-23 1999-08-25 Cilag AG International Liposomale Erythropoietin-Dispersion
WO1999052543A2 (en) * 1998-04-08 1999-10-21 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising erythropoietin for treatment of cancer
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
WO2000009713A1 (en) * 1998-08-13 2000-02-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Adenoviral vectors encoding erythropoietin and their use in gene therapy
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6214824B1 (en) * 1998-09-16 2001-04-10 Douglas M. Evans Use of amiloride for treating cancer
WO2001092313A2 (en) * 2000-06-01 2001-12-06 United States Environmental Protection Agency Methods for isolating and using fungal hemolysins
US6355410B1 (en) * 1998-06-03 2002-03-12 Ivan N Rich Method of reducing cell proliferation by inhibiting the Na+/H+ exchanger and inducing apoptosis
WO2002053580A2 (en) * 2000-12-29 2002-07-11 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
WO2003024183A2 (en) * 2001-09-14 2003-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same
WO2003057242A1 (en) * 2002-01-09 2003-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221669B1 (en) * 1994-10-19 2001-04-24 Lifecell Corporation Prolonged preservation of blood platelets

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB611518A (en) * 1945-11-20 1948-11-01 Lilly Co Eli Manufacture of quinacrine
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
EP0310410A2 (de) * 1987-10-02 1989-04-05 Kawate, Tsuneyoshi Kalziumbeschleunigte Kalium-Flut-Kontrolle von geschädigten Körperzellen
WO1992021362A1 (en) * 1991-06-03 1992-12-10 Farmitalia Carlo Erba S.R.L. Nerve growth factor for use in the prevention and treatment of viral infections
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
EP0688766A1 (de) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0799836A1 (de) * 1994-12-29 1997-10-08 Yamanouchi Pharmaceutical Co. Ltd. Neuer monoklonaler antikörper welcher einen inhibitorischen effekt auf die typ ii phospholipase a2 zeigt und ein ptotein welches einen teil von diesem beinhaltet
WO1997017087A1 (en) * 1995-11-07 1997-05-15 Genentech, Inc. Stabilizing formulation for ngf
WO1999011291A1 (en) * 1997-09-04 1999-03-11 The Trustees Of The University Of Pennsylvania A method of inducing apoptosis in human brain tumor cells using nerve growth factor
EP0937456A1 (de) * 1998-02-23 1999-08-25 Cilag AG International Liposomale Erythropoietin-Dispersion
WO1999052543A2 (en) * 1998-04-08 1999-10-21 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising erythropoietin for treatment of cancer
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
US6355410B1 (en) * 1998-06-03 2002-03-12 Ivan N Rich Method of reducing cell proliferation by inhibiting the Na+/H+ exchanger and inducing apoptosis
WO2000009713A1 (en) * 1998-08-13 2000-02-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Adenoviral vectors encoding erythropoietin and their use in gene therapy
US6214824B1 (en) * 1998-09-16 2001-04-10 Douglas M. Evans Use of amiloride for treating cancer
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001092313A2 (en) * 2000-06-01 2001-12-06 United States Environmental Protection Agency Methods for isolating and using fungal hemolysins
WO2002053580A2 (en) * 2000-12-29 2002-07-11 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
WO2003024183A2 (en) * 2001-09-14 2003-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same
WO2003057242A1 (en) * 2002-01-09 2003-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EWART GARY D ET AL: "Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu.", EUROPEAN BIOPHYSICS JOURNAL: EBJ. GERMANY MAR 2002, vol. 31, no. 1, March 2002 (2002-03-01), pages 26 - 35, XP002257221, ISSN: 0175-7571 *
MUNCH-ELLINGSEN JENS ET AL: "Equal reduction in infarct size by ethylisopropyl-amiloride pretreatment and ischemic preconditioning in the in situ rabbit heart.", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 186, no. 1-2, 1998, pages 13 - 18, XP002257222, ISSN: 0300-8177 *
PHILLIS J W ET AL: "5-(N-Ethyl-N-isopropyl)-amiloride, an Na+-H+ exchange inhibitor, protects gerbil hippocampal neurons from ischemic injury.", BRAIN RESEARCH, vol. 839, no. 1, 21 August 1999 (1999-08-21), pages 199 - 202, XP002257220, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
DE10219545A1 (de) 2003-11-06
AU2003232212A8 (en) 2003-11-10
EP1530473A2 (de) 2005-05-18
WO2003090665A2 (de) 2003-11-06
AU2003232212A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1511730B8 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
WO2003080582A3 (de) Fredericamycin-derivate
AU2003286567A1 (en) Methods for the treatment of skin disorders
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
EP1487446A4 (de) Bicyclische heterocyclen zur behandlung von diabetes und anderen erkrankungen
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
WO2001098279A3 (en) Bis-arylsulfones
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
WO2004084932A3 (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
AU2003273843A1 (en) Use of skin-protecting substances
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2000061231A3 (en) Medical use
WO2003090665A3 (de) Regulation der erythrozyten-apoptose
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
WO2007015173A3 (en) Inflammation
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
HUP0201287A3 (en) Preventive or therapeutic drugs for various eosinphilia-related diseases containing quinazoline derivative chymase inhibitors as the active ingredient
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2004112690A3 (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2003747127

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003747127

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP